Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026)

ArriVent BioPharma has reported Net Cash Flow over the past 4 years, most recently at $16.6 million for Q1 2026.

  • Quarterly results put Net Cash Flow at $16.6 million for Q1 2026, up 167.8% from a year ago — trailing twelve months through Mar 2026 was $12.2 million (up 116.3% YoY), and the annual figure for FY2025 was -$28.8 million, up 62.21%.
  • Net Cash Flow reached $16.6 million in Q1 2026 per AVBP's latest filing, up from -$67.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $167.0 million in Q1 2024 and bottomed at -$67.1 million in Q4 2025.
  • Median Net Cash Flow over the past 4 years was -$15.8 million (2024), compared with a mean of $7.0 million.
  • The largest annual shift saw Net Cash Flow soared 494.57% in 2024 before it tumbled 317.05% in 2025.
  • Over 4 years, Net Cash Flow stood at -$16.0 million in 2023, then dropped by 0.8% to -$16.1 million in 2024, then crashed by 317.05% to -$67.1 million in 2025, then skyrocketed by 124.67% to $16.6 million in 2026.
  • Business Quant data shows Net Cash Flow for AVBP at $16.6 million in Q1 2026, -$67.1 million in Q4 2025, and -$93000.0 in Q3 2025.